FDA Approves Novartis' Pluvicto Combo For Metastatic Hormone-sensitive Prostate Cancer

BASEL (dpa-AFX) - Novartis (NVS) announced that the U.S. Food and Drug Administration approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inh...